Sargramostim (GM-CSF)
Sponsors
Sellas Life Sciences Group Inc., M.D. Anderson Cancer Center, Mayo Clinic, H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute
Conditions
Acute myeloid leukemia (AML) in second or later complete remission (CR2) or
second or later complete remission with incomplete platelet recovery (CRp2)LeukemiaLeukemia, Myeloid, ChronicLymphomaMetastatic MelanomaMultiple Myeloma and Plasma Cell NeoplasmStage III MelanomaStage IV Melanoma
Phase 1
Phase 2
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
CompletedNCT00323557
Start: 2004-06-30End: 2011-05-31Updated: 2012-12-05
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma
CompletedNCT00411086
Start: 2006-11-30End: 2016-11-30Updated: 2017-12-05
Sargramostim (GM-CSF) + PD-1
WithdrawnNCT04703426
Start: 2021-04-16End: 2025-06-09Updated: 2023-05-22
Phase 3
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
CompletedNCT00050531
Start: 2003-04-30End: 2015-08-31Updated: 2016-05-11
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Active, not recruitingCTIS2024-516405-23-00
Start: 2021-06-08Target: 101Updated: 2025-01-16